Cory Watson Is No Longer Taking These Cases
Were you or a loved one diagnosed with cancer after taking Belviq?
If you or someone you know developed cancer after taking Belviq, contact us immediately. Our experienced drug injury lawyers can help you pursue justice and compensation in a Belviq lawsuit.
Call (877) 562-0000 today or complete our FREE initial case consultation form on this page.
The nationally recognized drug injury lawyers at Cory Watson Attorneys are actively investigating claims on behalf of patients who developed cancer after taking the prescription weight-loss drug Belviq.
Does Belviq Cause Cancer?
According to a new study, weight loss medication Belviq has been linked to an increased risk of cancer. In addition, the U.S. Food & Drug Administration (FDA) requested that the manufacturer of Belviq voluntarily recall the weight-loss drug from the U.S. market.
Belviq was designed as a prescription weight loss drug for those who were unable to lose weight through diet and exercise. The active ingredient was supposed to give users the feeling of being full, curbing their appetite.
However, there have been serious concerns about the safety of Belviq, which were not adequately disclosed by the drug manufacturer.
Types of Cancers Linked to Belviq
According to the FDA, a range of cancer types were reported in the clinical safety trial.
The experienced product liability lawyers at Cory Watson are taking legal action and investigating potential claims on behalf of former Belviq users diagnosed with:
- Pancreatic Cancer
- Colorectal Cancer
- Lung Cancer
Researchers are studying the possible Belviq links to increased risks of other cancers, including breast cancer and brain cancer. The FDA recommended that patients taking Belviq immediately stop taking the drug following research findings tying the medication to increased cancer risks.
Belviq Weight-Loss Drug Recalled for Cancer Risks
Belviq was first approved by the FDA in 2012 based on the requirement that the manufacturer Eisai complete a post-marketing safety trial. This double-blind, placebo-controlled clinical trial included 12,000 people over five years and revealed that patients taking the drug had an increased risk of cancer.
On February 13, 2020, the FDA pulled Belviq from the market due to the potential cancer risk.
It now appears that the drug manufacturer ignored clear signs about the Belviq cancer risk and placed their desire for profits before consumer safety.